Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Enzyme Inhibition and Medicinal Chemistry

• Publication date

  2007-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/14756360601072916PMID 17518346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

  2006cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006cited by this paper
• In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*

  2005cited by this paper
• Challenges and successes in developing new therapies for hepatitis C

  2005cited by this paper
• Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C

  2005cited by this paper
• Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors.

  2004cited by this paper
• In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

  2004influential reference
• Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

  2004cited by this paper
• Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

  2004cited by this paper
• Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

  2004cited by this paper
• Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals.

  2003influential reference
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

  2003cited by this paper
• Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

  2003cited by this paper
• Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors.

  2003influential reference
• Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).

  2002cited by this paper
• Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus.

  2002cited by this paper
• Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization.

  2001cited by this paper
• Inhibition of the Hepatitis C Virus NS3/4A Protease

  2000cited by this paper
• Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease.

  2000cited by this paper
• Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

  2000cited by this paper
• Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.

  1999cited by this paper
• Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding

  1999cited by this paper
• Peptide-based inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• Product inhibition of the hepatitis C virus NS3 protease.

  1998influential reference
• Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• The Metal Binding Site of the Hepatitis C Virus NS3 Protease

  1998cited by this paper
• Synthetic and Naturally Occurring Protease Inhibitors Containing an Electrophilic Carbonyl Group

  1993cited by this paper

• α-Ketoamides-based covalent inhibitors in drug discovery: Current status and synthetic methods.

  2026cites this paper
• Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues.

  2021cites this paper
• Enantioenriched quaternary α-pentafluoroethyl derivatives of alkyl 1-indanone-2-carboxylates.

  2020cites this paper
• Molecular Interaction Analysis for Discovery of Drugs Targeting Enzymes and for Resolving Biological Function

  2015cites this paper
• Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.

  2014cites this paper
• Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.

  2014cites this paper
• Enantioselective Synthesis of Spirooxindole α‐exo‐Methylene‐γ‐butyrolactones from 3‐OBoc‐Oxindoles

  2014cites this paper
• Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors

  2011cites this paper
• Peptidomimetic Enzyme Inhibitors : Targeting M. tuberculosis Ribonucleotide Reductase and Hepatitis C Virus NS3 Protease

  2010cites this paper
• Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.

  2010cites this paper
• Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.

  2009cites this paper
• Beta-amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors.

  2008cites this paper
• Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors.

  2007cites this paper
• Improved CoMFA Modeling by Optimization of Settings

  2006cites this paper